We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+11.77%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.63B
AUM Growth
-$1.1B
Cap. Flow
-$741M
Cap. Flow %
-20.41%
Top 10 Hldgs %
50.26%
Holding
130
New
22
Increased
12
Reduced
43
Closed
31

Top Buys

Rank Stock Value
1
JANX icon
Janux Therapeutics
JANX
+$43.3M
2
PODD icon
Insulet
PODD
+$22.7M
3
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$21.9M
4
SEPN
Septerna Inc
SEPN
+$17.7M
5
PEN icon
Penumbra
PEN
+$16.7M

Top Sells

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$88.3M
2
BHVN icon
Biohaven
BHVN
+$74.2M
3
TARS icon
Tarsus Pharmaceuticals
TARS
+$50.4M
4
APGE
Apogee Therapeutics
APGE
+$49.4M
5
APLT
Applied Therapeutics
APLT
+$44.8M

Sector Composition

Rank Sector Weight
1 Healthcare 98.92%
2 Miscellaneous 1.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALLO icon
101
Allogene Therapeutics
ALLO
$594M
– –
-2,725,000
Closed -$7.63M
ARQT icon
102
Arcutis Biotherapeutics
ARQT
$2.96B
– –
-1,358,500
Closed -$12.6M
BHVN icon
103
Biohaven
BHVN
$1.86B
– –
-1,485,232
Closed -$74.2M
DTIL icon
104
Precision BioSciences
DTIL
$182M
– –
-426,293
Closed -$3.82M
EXAS
105
DELISTED
Exact Sciences
EXAS
– –
-125,000
Closed -$8.52M
FATE icon
106
Fate Therapeutics
FATE
$282M
– –
-345,575
Closed -$1.21M
FULC icon
107
CALL
Fulcrum Therapeutics
FULC
$288M
– –
-1,500,000
Closed -$5.36M
GPCR icon
108
Structure Therapeutics
GPCR
$2.78B
– –
-34,852
Closed -$1.53M
ICLR icon
109
Icon
ICLR
$13.3B
– –
-44,353
Closed -$12.7M
IRON icon
110
Disc Medicine
IRON
$2.58B
– –
-387,017
Closed -$19M
KYMR icon
111
Kymera Therapeutics
KYMR
$9.41B
– –
-46,213
Closed -$2.19M
LIVN icon
112
LivaNova
LIVN
$4.38B
– –
-429,000
Closed -$22.5M
MDT icon
113
Medtronic
MDT
$120B
– –
-245,332
Closed -$22.1M
NVNO
114
enVVeno Medical
NVNO
$6.48M
– –
-19,838
Closed -$2.33M
ROIV icon
115
Roivant Sciences
ROIV
$28.5B
– –
-847,745
Closed -$9.78M
FLNA
116
PUT
Filana Therapeutics
FLNA
$33.6M
– –
-183,000
Closed -$5.39M
SWTX
117
DELISTED
SpringWorks Therapeutics
SWTX
– –
-692,263
Closed -$22.2M
TIL icon
118
Instil Bio
TIL
$48.9M
– –
-345,545
Closed -$23.3M
TYRA icon
119
Tyra Biosciences
TYRA
$1.52B
– –
-511,226
Closed -$12M
VRNA
120
CALL
DELISTED
Verona Pharma
VRNA
– –
-250,000
Closed -$7.19M
VRNA
121
PUT
DELISTED
Verona Pharma
VRNA
– –
-250,000
Closed -$7.19M
XBI icon
122
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
– –
-400,000
Closed -$39.5M
XFOR icon
123
X4 Pharmaceuticals
XFOR
$359M
– –
-118,182
Closed -$2.37M
XNCR icon
124
Xencor
XNCR
$1.77B
– –
-527,671
Closed -$10.6M
AVBP icon
125
ArriVent BioPharma
AVBP
$1.38B
– –
-415,000
Closed -$9.75M
2 3 4
5
6

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q4 2024 Portfolio in Review

As of Q4 2024, Perceptive Advisors held 130 positions worth $3.63B, down 23% from $4.73B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Perceptive Advisors withdrew a net $741M in Q4 2024, closing 31 positions and reducing 43 holdings. Its most notable exit was Biohaven, an estimated $74.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

Against the trend, Perceptive Advisors opened a new position in Janux Therapeutics worth $43.8M.

  • Perceptive Advisors's largest Q4 2024 buy was Janux Therapeutics: 817,895 shares worth $43.8M.
  • Perceptive Advisors added most to Insulet in Q4 2024, an estimated $22.7M increase.
  • Perceptive Advisors's biggest Q4 2024 reduction was Soleno Therapeutics, cutting an estimated $88.3M.
  • Perceptive Advisors fully exited Biohaven in Q4 2024, selling an estimated $74.2M.
  • Perceptive Advisors's ten largest holdings make up 50% of its $3.63B portfolio in Q4 2024.
  • Perceptive Advisors opened 22 new positions and closed 31 in Q4 2024.
  • Perceptive Advisors's portfolio value fell 23% quarter-over-quarter to $3.63B.

Based on Perceptive Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.